Cargando…

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ting-Ting, Chen, Ye-Hui, Wu, Yu-Peng, Chen, Shao-Zhan, Li, Xiao-Dong, Lin, Yun-Zhi, Chen, Shao-Hao, Zheng, Qing-Shui, Wei, Yong, Xu, Ning, Xue, Xue-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775699/
https://www.ncbi.nlm.nih.gov/pubmed/31632505
http://dx.doi.org/10.7150/jca.30731
_version_ 1783456304705044480
author Lin, Ting-Ting
Chen, Ye-Hui
Wu, Yu-Peng
Chen, Shao-Zhan
Li, Xiao-Dong
Lin, Yun-Zhi
Chen, Shao-Hao
Zheng, Qing-Shui
Wei, Yong
Xu, Ning
Xue, Xue-Yi
author_facet Lin, Ting-Ting
Chen, Ye-Hui
Wu, Yu-Peng
Chen, Shao-Zhan
Li, Xiao-Dong
Lin, Yun-Zhi
Chen, Shao-Hao
Zheng, Qing-Shui
Wei, Yong
Xu, Ning
Xue, Xue-Yi
author_sort Lin, Ting-Ting
collection PubMed
description Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015 at the First Affiliated Hospital of Fujian Medical University. Univariate and multivariate Cox regression analysis were used to explore the risk factors for progression to CRPC. Kaplan-Meier analysis and log-rank test were used to evaluate the difference in progression-free survival (PFS). Results: A total of 121 (56.0%) patients who underwent ADT showed progression to CRPC. Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients. Kaplan-Meier analysis demonstrated that patients in Gleason grade group ≥3, nPSA >0.2 ng/ml and TTN <6 months had shorter PFS. Conclusion: This study demonstrated that Gleason grade group, nPSA and TTN were risk factors for progression to CRPC. Patients with higher Gleason grade group, higher nPSA and shorter TTN have shorter PFS and higher risk of progression to CRPC after ADT.
format Online
Article
Text
id pubmed-6775699
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-67756992019-10-18 Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients Lin, Ting-Ting Chen, Ye-Hui Wu, Yu-Peng Chen, Shao-Zhan Li, Xiao-Dong Lin, Yun-Zhi Chen, Shao-Hao Zheng, Qing-Shui Wei, Yong Xu, Ning Xue, Xue-Yi J Cancer Research Paper Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015 at the First Affiliated Hospital of Fujian Medical University. Univariate and multivariate Cox regression analysis were used to explore the risk factors for progression to CRPC. Kaplan-Meier analysis and log-rank test were used to evaluate the difference in progression-free survival (PFS). Results: A total of 121 (56.0%) patients who underwent ADT showed progression to CRPC. Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients. Kaplan-Meier analysis demonstrated that patients in Gleason grade group ≥3, nPSA >0.2 ng/ml and TTN <6 months had shorter PFS. Conclusion: This study demonstrated that Gleason grade group, nPSA and TTN were risk factors for progression to CRPC. Patients with higher Gleason grade group, higher nPSA and shorter TTN have shorter PFS and higher risk of progression to CRPC after ADT. Ivyspring International Publisher 2019-09-07 /pmc/articles/PMC6775699/ /pubmed/31632505 http://dx.doi.org/10.7150/jca.30731 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Lin, Ting-Ting
Chen, Ye-Hui
Wu, Yu-Peng
Chen, Shao-Zhan
Li, Xiao-Dong
Lin, Yun-Zhi
Chen, Shao-Hao
Zheng, Qing-Shui
Wei, Yong
Xu, Ning
Xue, Xue-Yi
Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title_full Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title_fullStr Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title_full_unstemmed Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title_short Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
title_sort risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775699/
https://www.ncbi.nlm.nih.gov/pubmed/31632505
http://dx.doi.org/10.7150/jca.30731
work_keys_str_mv AT lintingting riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT chenyehui riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT wuyupeng riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT chenshaozhan riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT lixiaodong riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT linyunzhi riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT chenshaohao riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT zhengqingshui riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT weiyong riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT xuning riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients
AT xuexueyi riskfactorsforprogressiontocastrationresistantprostatecancerinmetastaticprostatecancerpatients